drugset / Trial / NCT01248780

Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT01248780

Phase 3 Completed 264 enrolled Centocor, Inc. Schering-Plough · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of golimumab in Chinese patients with rheumatoid arthritis.

Timeline

Start
2010-09
Primary completion
2011-10
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Golimumab Monoclonal antibody 50 mg Subcutaneous
Background Methotrexate Small molecule Oral

Indications